I'm a Prometic (PLI.to) shareholder. I went to the AGM last may. It lasted more than two hours.
I thnink there's many factors explaining why investors don't see the same potential in PTK.
- They are listed on the TSX
- Even though the science/mechanism behind their drug candidates maybe complicated, the company makes awesome communication tools.
Just take a look at the video they shared at the AGM for one of their drug candidate :
http://www.prometic.com/wp-content/uploads/2016/05/ProMetic_PBI4050_animation_04.mp4
Also, look at the AGM presentation (skip the first part and start at page 30), this is the kind of stuff that really appeal to almost any human being. They make it easy to understand.
http://www.prometic.com/wp-content/uploads/2016/05/Prometic-AGM-presentation-May-11-2016-EV-FINAL.pdf
- Two other companies targeting some of the same diseases as Prometic got bought for 5 and 8 billions $ in 2015. Just for one drug. Prometic will end up with 5 to 8 drugs.
We know the same business case could be made for PTK, but not enough investors have heard of our company.
- And lastly, they are followed by almost every financial institutions in Canada, giving the company a lot of exposure in the investment community.
http://www.prometic.com/investors/analysts/
